Cargando…
Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study
INTRODUCTION: Current criteria for early diagnosis of coagulopathy in sepsis are limited. We postulated that coagulopathy is already complicated with sepsis in the initial phase, and severe coagulopathy or disseminated intravascular coagulation (DIC) becomes overt after progressive consumption of pl...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056264/ https://www.ncbi.nlm.nih.gov/pubmed/24410881 http://dx.doi.org/10.1186/cc13190 |
_version_ | 1782320803982868480 |
---|---|
author | Koyama, Kansuke Madoiwa, Seiji Nunomiya, Shin Koinuma, Toshitaka Wada, Masahiko Sakata, Asuka Ohmori, Tsukasa Mimuro, Jun Sakata, Yoichi |
author_facet | Koyama, Kansuke Madoiwa, Seiji Nunomiya, Shin Koinuma, Toshitaka Wada, Masahiko Sakata, Asuka Ohmori, Tsukasa Mimuro, Jun Sakata, Yoichi |
author_sort | Koyama, Kansuke |
collection | PubMed |
description | INTRODUCTION: Current criteria for early diagnosis of coagulopathy in sepsis are limited. We postulated that coagulopathy is already complicated with sepsis in the initial phase, and severe coagulopathy or disseminated intravascular coagulation (DIC) becomes overt after progressive consumption of platelet and coagulation factors. To determine early diagnostic markers for severe coagulopathy, we evaluated plasma biomarkers for association with subsequent development of overt DIC in patients with sepsis. METHODS: A single-center, prospective observational study was conducted in an adult ICU at a university hospital. Plasma samples were obtained from patients with sepsis at ICU admission. Fourteen biomarkers including global markers (platelet count, prothrombin time, activated partial thromboplastin time, fibrinogen and fibrin degradation product (FDP)); markers of thrombin generation (thrombin-antithrombin complex (TAT) and soluble fibrin); markers of anticoagulants (protein C (PC) and antithrombin); markers of fibrinolysis (plasminogen, α(2)-plasmin inhibitor (PI), plasmin-α(2)-PI complex, and plasminogen activator inhibitor (PAI)-1); and a marker of endothelial activation (soluble E-selectin) were assayed. Patients who had overt DIC at baseline were excluded, and the remaining patients were followed for development of overt DIC in 5 days, and for mortality in 28 days. RESULTS: A total of 77 patients were enrolled, and 37 developed overt DIC within the following 5 days. Most patients demonstrated hemostatic abnormalities at baseline with 98.7% TAT, 97.4% FDP and 88.3% PC. Most hemostatic biomarkers at baseline were significantly associated with subsequent development of overt DIC. Notably, TAT, PAI-1 and PC discriminated well between patients with and without developing overt DIC (area under the receiver operating characteristic curve (AUROC), 0.77 (95% confidence interval, 0.64 to 0.86); 0.87 (0.78 to 0.92); 0.85 (0.76 to 0.91), respectively), and using the three together, significantly improved the AUROC up to 0.95 (vs. TAT, PAI-1, and PC). Among the significant diagnostic markers for overt DIC, TAT and PAI-1 were also good predictors of 28-day mortality (AUROC, 0.77 and 0.81, respectively). CONCLUSIONS: Severe coagulation and fibrinolytic abnormalities on ICU admission were associated with subsequent development of overt DIC. A single measurement of TAT, PAI-1, and PC activity could identify patients with ongoing severe coagulopathy, early in the course of sepsis. |
format | Online Article Text |
id | pubmed-4056264 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40562642014-06-14 Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study Koyama, Kansuke Madoiwa, Seiji Nunomiya, Shin Koinuma, Toshitaka Wada, Masahiko Sakata, Asuka Ohmori, Tsukasa Mimuro, Jun Sakata, Yoichi Crit Care Research INTRODUCTION: Current criteria for early diagnosis of coagulopathy in sepsis are limited. We postulated that coagulopathy is already complicated with sepsis in the initial phase, and severe coagulopathy or disseminated intravascular coagulation (DIC) becomes overt after progressive consumption of platelet and coagulation factors. To determine early diagnostic markers for severe coagulopathy, we evaluated plasma biomarkers for association with subsequent development of overt DIC in patients with sepsis. METHODS: A single-center, prospective observational study was conducted in an adult ICU at a university hospital. Plasma samples were obtained from patients with sepsis at ICU admission. Fourteen biomarkers including global markers (platelet count, prothrombin time, activated partial thromboplastin time, fibrinogen and fibrin degradation product (FDP)); markers of thrombin generation (thrombin-antithrombin complex (TAT) and soluble fibrin); markers of anticoagulants (protein C (PC) and antithrombin); markers of fibrinolysis (plasminogen, α(2)-plasmin inhibitor (PI), plasmin-α(2)-PI complex, and plasminogen activator inhibitor (PAI)-1); and a marker of endothelial activation (soluble E-selectin) were assayed. Patients who had overt DIC at baseline were excluded, and the remaining patients were followed for development of overt DIC in 5 days, and for mortality in 28 days. RESULTS: A total of 77 patients were enrolled, and 37 developed overt DIC within the following 5 days. Most patients demonstrated hemostatic abnormalities at baseline with 98.7% TAT, 97.4% FDP and 88.3% PC. Most hemostatic biomarkers at baseline were significantly associated with subsequent development of overt DIC. Notably, TAT, PAI-1 and PC discriminated well between patients with and without developing overt DIC (area under the receiver operating characteristic curve (AUROC), 0.77 (95% confidence interval, 0.64 to 0.86); 0.87 (0.78 to 0.92); 0.85 (0.76 to 0.91), respectively), and using the three together, significantly improved the AUROC up to 0.95 (vs. TAT, PAI-1, and PC). Among the significant diagnostic markers for overt DIC, TAT and PAI-1 were also good predictors of 28-day mortality (AUROC, 0.77 and 0.81, respectively). CONCLUSIONS: Severe coagulation and fibrinolytic abnormalities on ICU admission were associated with subsequent development of overt DIC. A single measurement of TAT, PAI-1, and PC activity could identify patients with ongoing severe coagulopathy, early in the course of sepsis. BioMed Central 2014 2014-01-13 /pmc/articles/PMC4056264/ /pubmed/24410881 http://dx.doi.org/10.1186/cc13190 Text en Copyright © 2014 Koyama et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Koyama, Kansuke Madoiwa, Seiji Nunomiya, Shin Koinuma, Toshitaka Wada, Masahiko Sakata, Asuka Ohmori, Tsukasa Mimuro, Jun Sakata, Yoichi Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study |
title | Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study |
title_full | Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study |
title_fullStr | Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study |
title_full_unstemmed | Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study |
title_short | Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study |
title_sort | combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein c activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056264/ https://www.ncbi.nlm.nih.gov/pubmed/24410881 http://dx.doi.org/10.1186/cc13190 |
work_keys_str_mv | AT koyamakansuke combinationofthrombinantithrombincomplexplasminogenactivatorinhibitor1andproteincactivityforearlyidentificationofseverecoagulopathyininitialphaseofsepsisaprospectiveobservationalstudy AT madoiwaseiji combinationofthrombinantithrombincomplexplasminogenactivatorinhibitor1andproteincactivityforearlyidentificationofseverecoagulopathyininitialphaseofsepsisaprospectiveobservationalstudy AT nunomiyashin combinationofthrombinantithrombincomplexplasminogenactivatorinhibitor1andproteincactivityforearlyidentificationofseverecoagulopathyininitialphaseofsepsisaprospectiveobservationalstudy AT koinumatoshitaka combinationofthrombinantithrombincomplexplasminogenactivatorinhibitor1andproteincactivityforearlyidentificationofseverecoagulopathyininitialphaseofsepsisaprospectiveobservationalstudy AT wadamasahiko combinationofthrombinantithrombincomplexplasminogenactivatorinhibitor1andproteincactivityforearlyidentificationofseverecoagulopathyininitialphaseofsepsisaprospectiveobservationalstudy AT sakataasuka combinationofthrombinantithrombincomplexplasminogenactivatorinhibitor1andproteincactivityforearlyidentificationofseverecoagulopathyininitialphaseofsepsisaprospectiveobservationalstudy AT ohmoritsukasa combinationofthrombinantithrombincomplexplasminogenactivatorinhibitor1andproteincactivityforearlyidentificationofseverecoagulopathyininitialphaseofsepsisaprospectiveobservationalstudy AT mimurojun combinationofthrombinantithrombincomplexplasminogenactivatorinhibitor1andproteincactivityforearlyidentificationofseverecoagulopathyininitialphaseofsepsisaprospectiveobservationalstudy AT sakatayoichi combinationofthrombinantithrombincomplexplasminogenactivatorinhibitor1andproteincactivityforearlyidentificationofseverecoagulopathyininitialphaseofsepsisaprospectiveobservationalstudy |